Orforglipron UK Availability 2026: The New Oral GLP-1 Pill Explained

Orforglipron is the first non-peptide oral GLP-1 with strong Phase 3 weight-loss data. UK availability is most likely from late 2026.

You are paying around 280 pounds a month for the highest dose of Mounjaro privately, and a headline lands in your phone. Eli Lilly has just won US approval for a once-daily tablet in the same drug class. So three questions come straight back. When will this tablet, orforglipron, reach the UK? Will it cost less than the injection? And does it work as well? Orforglipron is the first non-peptide oral GLP-1 with strong Phase 3 weight-loss data. It went on sale in the United States in April 2026 as Foundayo. Eli Lilly is expected to file with the MHRA around the middle of 2026, which puts a UK private launch in late 2026 territory. This guide sets out what the trials showed, how the tablet is taken, what side effects to expect, the realistic UK timeline, and how the pill compares with the injection pens you can already get.

What orforglipron is and how it works

Orforglipron is a once-daily tablet. It is a GLP-1 receptor agonist, so it mimics a gut hormone called glucagon-like peptide 1. That hormone is released after you eat and does three things. It nudges the pancreas to release insulin. It slows down how fast your stomach empties. It acts on the brain to reduce appetite. The same core mechanism powers the weekly injections Wegovy (semaglutide) and Mounjaro (tirzepatide), the daily injection Saxenda (liraglutide), and the existing daily tablet Rybelsus (oral semaglutide).

The important difference is the chemistry. Semaglutide, tirzepatide and liraglutide are peptides. Your gut breaks peptides down, so they have to be injected. Rybelsus is also a peptide. To get any of it to absorb, you take it on an empty stomach with a small sip of water, then wait 30 minutes before eating or drinking anything else. Orforglipron is not a peptide. It is a small molecule. You take it with or without food, no fasting and no special water rule. Trial protocols built the dose up step by step to manage side effects, testing 6 mg, 12 mg and 36 mg once a day. The 36 mg dose did the most for weight loss and blood sugar. Because it is a standard tablet, manufacturing is simpler and supply easier than the peptide injections. That is a big part of why clinicians and regulators have been watching this drug.

When orforglipron will be available in the UK

This is the question most readers want answered. In the United States, the Food and Drug Administration approved orforglipron in April 2026 for chronic weight management in adults with obesity, or with overweight and at least one weight-related health condition. The brand name there is Foundayo. Eli Lilly sent its weight-management dossier to global regulators around the end of 2025, and a separate type 2 diabetes submission follows in 2026.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) is expected to receive the application around the middle of 2026. A standard MHRA review takes 150 to 210 days. The MHRA also runs an International Recognition Procedure that lets it lean on the work already done by trusted partners such as the FDA, which can cut the UK timeline to about two to four months. If orforglipron qualifies for that route and the dossier is clean, a UK marketing authorisation is realistic in late 2026. After that, private clinics and online doctors can begin prescribing. NHS access is a separate, slower track. The National Institute for Health and Care Excellence (NICE) has to do a cost-effectiveness appraisal after licensing, which makes an NHS launch unlikely before 2027.

As of May 2026, orforglipron has no UK licence. It cannot be lawfully prescribed or sold here. Any provider offering it now is operating outside the legal and safety framework set by the MHRA.

Phase 3 trial results in plain terms

The ATTAIN and ACHIEVE programmes tested orforglipron in thousands of people. ATTAIN-1 was a 72-week study in adults with obesity who did not have type 2 diabetes. All three doses beat a placebo tablet. The 36 mg dose led to an average weight loss of about 12.4 percent of body weight, or roughly 27.3 lbs (12.4 kg). ATTAIN-2 tested people with obesity and type 2 diabetes, and again all doses produced clinically meaningful weight loss, although the average was a little lower than in non-diabetic adults. That gap is normal for GLP-1 trials.

The ACHIEVE trials focused on blood sugar in type 2 diabetes. ACHIEVE-1 showed that the 36 mg dose lowered HbA1c (a measure of long-term blood sugar) by 1.3 to 1.6 percent over 40 weeks, with more than 65 percent of participants reaching HbA1c at or below 6.5 percent, plus an average weight loss of 7.9 percent. ACHIEVE-3 showed orforglipron outperformed the oral tablet Rybelsus on both HbA1c and weight. ACHIEVE-4 showed sustained outcomes against long-acting insulin.

Side effects were the ones you would expect for this class. Mostly stomach and gut: nausea, vomiting, diarrhoea, constipation, indigestion. They were most common when the dose was bumped up, and usually settled in a few weeks. Pancreatitis and gallbladder events were rare. No new safety surprises came out of the data.

How orforglipron compares with Mounjaro and Wegovy

Lined up by top-dose effect on weight, the order is clear. Mounjaro (tirzepatide) is the most effective with about 22.5 percent body weight reduction over 72 weeks. Wegovy (semaglutide) sits in the middle at around 15 percent over 68 weeks. Orforglipron comes in lower, with about 12.4 percent over 72 weeks. If your goal is maximum weight loss, tirzepatide still wins.

That said, three practical reasons mean a lot of UK private patients will probably take orforglipron seriously once it lands. First, the format. A daily tablet is more discreet, takes needles out of the picture, and removes the cold storage and sharps bin. Second, supply. Tablet manufacturing is simpler than peptide injection manufacturing. Eli Lilly has committed to a global scale-up, which should help avoid the worst of the pen shortages that hit Mounjaro and Wegovy through 2023 and 2024. Third, price. UK private pricing is not set yet, but orforglipron will most likely be priced below 15 mg Mounjaro and broadly competitive with maintenance Wegovy. If injections are the friction or cost is the squeeze, swapping for a tablet at a moderate cost in effect can make sense. Switch-trial data also shows people who move from an injectable GLP-1 onto orforglipron tend to keep their weight off, which matters for anyone thinking of switching once the tablet is licensed.

Likely UK pricing and access scenarios in 2026 and 2027

Two paths to consider.

Private prescribing. If the MHRA grants a licence in late 2026, expect the major UK online doctors and pharmacies (Boots Online Doctor, Superdrug Online Doctor, Pharmacy2U, LloydsPharmacy Online Doctor, Asda Online Doctor) to start offering orforglipron from late 2026 or early 2027. Predicting the launch price is guesswork, but a band of 90 to 180 pounds a month is reasonable. That sits below 15 mg Mounjaro, which was 270 to 340 pounds a month in May 2026, and broadly in line with maintenance Wegovy. Demand will be heavy at launch, so expect waiting lists and stock limits.

NHS access. Slower. NICE only starts its cost-effectiveness review after MHRA licensing. NICE tends to prioritise the most severe end of obesity. Realistic NHS access through the existing Cohort 1 or Cohort 2 pathways is 2027 at the earliest, with a phased rollout similar to Mounjaro and Wegovy. Patients are identified through GP records, not by self-referral. The useful thing to do now is make sure your BMI, comorbidities and ethnicity are correctly recorded at your next NHS review, so the system catches you when an orforglipron pathway opens.

Side effects, contraindications and the MHRA black triangle

The safety profile from trials is in line with the rest of the GLP-1 class. Most common: gastrointestinal side effects, nausea, vomiting, diarrhoea, constipation, indigestion, abdominal discomfort. Mild to moderate, peaks soon after a dose step, usually settles within two to four weeks. Less common: gallstones and gallbladder inflammation. Rare but serious: pancreatitis. None of this is new for the GLP-1 class.

On UK launch, orforglipron will almost certainly come under the MHRA black triangle scheme. That puts it on enhanced monitoring and means any suspected side effect should be reported via the Yellow Card system. Contraindications will likely mirror the rest of the class: do not use in pregnancy or while breastfeeding, do not use if there is a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Use with caution in previous pancreatitis, severe gastroparesis or significant gallbladder disease.

One practical detail worth flagging. GLP-1 drugs slow stomach emptying, which can change how other oral medicines are absorbed. If you take warfarin, levothyroxine, oral contraceptives or anti-epileptic drugs, ask your prescriber for a specific interaction review when starting orforglipron and after every dose increase. The other quiet risk across this class is loss of muscle and bone mass during significant weight loss, especially in older adults. Adequate protein (about 1.0 to 1.5 grams per kg body weight) and resistance training twice a week make a real difference.

What to do while you wait for orforglipron in the UK

A calm checklist for the months ahead.

First, do not try to buy orforglipron from any UK source before it is licensed. As of May 2026 it is an unlicensed medicine. Any sale is unlawful, and the product is outside the MHRA safety net. High-demand medicines attract counterfeits.

Second, if you are already on Mounjaro or Wegovy, do not stop or change your treatment in anticipation of the new tablet. The earliest likely UK launch is late 2026. Continuity is important. Stopping a GLP-1 abruptly is often linked with weight regain.

Third, review your current private prescription. If cost is the issue, compare prices at the same dose across Boots, Superdrug, Pharmacy2U, LloydsPharmacy and Asda. A switch at the same dose can sometimes save 30 to 50 pounds a month.

Fourth, check whether you might qualify for NHS Cohort 1. That requires a BMI of 40 or above (37.5 or above for South Asian, Black African or Chinese ethnicity) and at least four qualifying comorbidities. If you might be eligible, make sure your GP record reflects your conditions correctly.

Fifth, layer the basics on top of any medication: enough protein, daily walking, resistance training twice a week, decent sleep, sensible alcohol intake. Weight-loss medication outcomes are better in people who do these things.

Sixth, lean on credible sources for updates. The MHRA news feed and trusted clinical blogs (including this one) will cover the orforglipron UK licensing decision when it lands. Social media is not the place to make a treatment decision.

Frequently Asked Questions

When will orforglipron be available in the UK?

Eli Lilly is expected to file orforglipron with the MHRA in mid 2026. The standard MHRA review takes 150 to 210 days. Through the International Recognition Procedure, which leans on the FDA review, a UK licence could land in late 2026. Private prescribing is therefore most likely from late 2026 or early 2027. NHS access through NICE is unlikely before 2027 at the earliest. As of May 2026, orforglipron has no UK marketing authorisation.

Is orforglipron approved in the United States?

Yes. The FDA approved orforglipron in April 2026 under the brand name Foundayo, for chronic weight management in adults with obesity or with overweight plus at least one weight-related condition. A separate FDA submission for type 2 diabetes is expected in 2026. Foundayo is on US pharmacy shelves, but it cannot be legally imported into the UK by individuals or providers without MHRA authorisation.

How much weight does orforglipron help you lose?

In ATTAIN-1, the 36 mg dose produced an average weight loss of about 12.4 percent of body weight over 72 weeks, or roughly 27.3 lbs (12.4 kg). Lower 6 mg and 12 mg doses gave smaller but still clinically meaningful reductions. In people with type 2 diabetes, weight loss was a little lower, which is consistent across all GLP-1 medicines. Real-world results outside trial conditions are usually a touch lower again.

How does orforglipron compare with Mounjaro and Wegovy?

At top doses, Mounjaro (tirzepatide) is the most effective at about 22.5 percent over 72 weeks. Wegovy (semaglutide) is next at about 15 percent over 68 weeks. Orforglipron is at the lower end with about 12.4 percent over 72 weeks, but it is a tablet. People who want the maximum effect will likely stay on tirzepatide. People who want a tablet, no injections and lower cost will look at orforglipron seriously.

What side effects does orforglipron cause?

Trials reported mostly stomach side effects: nausea, vomiting, diarrhoea, constipation and indigestion. These peaked at dose increases and usually settled within a few weeks. Less common: gallbladder problems. Rare: pancreatitis, which is a known rare risk for the whole GLP-1 class. No new safety signals appeared. On UK launch the drug will almost certainly be under the MHRA black triangle, so any side effect should be reported via Yellow Card.

Can I buy orforglipron in the UK now?

No. As of May 2026, orforglipron is not licensed in the UK. It cannot be lawfully sold or prescribed here. Any website or provider claiming to supply it is operating outside the law and outside MHRA oversight. The Yellow Card adverse-event scheme only covers licensed products, so any safety issue from an unlicensed import would not be tracked. Wait for the MHRA licensing decision.

Should I switch from Mounjaro to orforglipron when it arrives?

Talk to your prescribing clinician before any change. Switch-trial data suggests weight loss is maintained when patients move from injectable tirzepatide or semaglutide to orforglipron, but the top dose of Mounjaro is more effective than the top dose of orforglipron. If your reason for switching is cost or injection burden, orforglipron may be a sensible choice. If you need the strongest possible effect, staying on Mounjaro is reasonable. Do not change your medication based on social media chatter.

This article is informational only and does not replace personalised advice from your GP, pharmacist, or another qualified healthcare professional.